Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Open-label Trial of Tinostamustine Conditioning and Autologous Stem Cell Transplantation for Salvage Treatment in Relapsed / Refractory Multiple Myeloma (TITANIUM 1)

Trial Profile

Phase 1/2 Open-label Trial of Tinostamustine Conditioning and Autologous Stem Cell Transplantation for Salvage Treatment in Relapsed / Refractory Multiple Myeloma (TITANIUM 1)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 14 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tinostamustine (Primary)
  • Indications Cutaneous T-cell lymphoma; Hodgkin's disease; Multiple myeloma; Peripheral T-cell lymphoma; T-cell prolymphocytic leukaemia
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms TITANIUM 1
  • Sponsors Mundipharma EDO; Mundipharma GmbH
  • Most Recent Events

    • 11 Jun 2019 Status changed from active, no longer recruiting to discontinued.
    • 14 Mar 2019 Status changed from recruiting to active, no longer recruiting.
    • 05 Mar 2019 According to an Imbrium Therapeutics media release, each study arm will run separately, with results to be submitted for upcoming medical meetings.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top